Concepedia

Keiko Nakajima

KN

Statistics

Publications

27

Citations

2.5K

H-Index

19

Active since

1983

Affiliations

Bayer (United States)(Current)

Fudan University

Huazhong University of Science and Technology

Kindai University

Nihon University

Keiko Nakajima is an author at Bayer (United States) specializing in medicine, oncology, and radiation oncology.

ORCID

Top concepts

Publications per year

1983–2024

27

Publications

27

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies

Jordi Bruix, Ann‐Lii Cheng, Gerold Meinhardt et al. · Journal of Hepatology · 2017 · 566 citations · Full text

Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

Jorge A. Marrero, Masatoshi Kudo, Alan P. Venook et al. · Journal of Hepatology · 2016 · 376 citations · Full text

, , +10

<scp>GIDEON</scp> (Global Investigation of therapeutic <scp>DE</scp> cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

Riccardo Lencioni, Masatoshi Kudo, Sheng‐Long Ye et al. · International Journal of Clinical Practice · 2013 · 222 citations · Full text

Acute Hydrothorax in Continuous Ambulatory Peritoneal Dialysis &amp;ndash; A Collaborative Study of 161 Centers

Yasuo Nomoto, Takao Suga, Keiko Nakajima et al. · American Journal of Nephrology · 1989 · 221 citations

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma

Junji Furuse, Hiroshi Ishii, Kohei Nakachi et al. · Cancer Science · 2007 · 193 citations · Full text

1–5 of 27